ATE553763T1 - Selektive a2a-rezeptorantagonisten zur behandlung von vorhofflimmern - Google Patents

Selektive a2a-rezeptorantagonisten zur behandlung von vorhofflimmern

Info

Publication number
ATE553763T1
ATE553763T1 AT06830873T AT06830873T ATE553763T1 AT E553763 T1 ATE553763 T1 AT E553763T1 AT 06830873 T AT06830873 T AT 06830873T AT 06830873 T AT06830873 T AT 06830873T AT E553763 T1 ATE553763 T1 AT E553763T1
Authority
AT
Austria
Prior art keywords
atrial fibrillation
receptor antagonists
selective
treatment
antagonists
Prior art date
Application number
AT06830873T
Other languages
German (de)
English (en)
Inventor
Fern Ndez Rafael Franco
Alferez Francisco Ciruela
Biset Carmen Lluoes
Christa Mueller
Cuscullola Joan Cinca
Leif Hove-Madsen
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Application granted granted Critical
Publication of ATE553763T1 publication Critical patent/ATE553763T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
AT06830873T 2005-10-14 2006-10-10 Selektive a2a-rezeptorantagonisten zur behandlung von vorhofflimmern ATE553763T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200502545A ES2273599B1 (es) 2005-10-14 2005-10-14 Compuestos para el tratamiento de la fibrilacion auricular.
PCT/ES2006/000564 WO2007045705A2 (es) 2005-10-14 2006-10-10 Compuestos para el tratamiento de la fibrilación auricular

Publications (1)

Publication Number Publication Date
ATE553763T1 true ATE553763T1 (de) 2012-05-15

Family

ID=37962872

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06830873T ATE553763T1 (de) 2005-10-14 2006-10-10 Selektive a2a-rezeptorantagonisten zur behandlung von vorhofflimmern

Country Status (13)

Country Link
US (1) US8012973B2 (enExample)
EP (1) EP1949903B8 (enExample)
JP (1) JP2009511551A (enExample)
CN (1) CN101325956B (enExample)
AT (1) ATE553763T1 (enExample)
AU (1) AU2006303240B2 (enExample)
BR (1) BRPI0617369A2 (enExample)
CA (1) CA2626020A1 (enExample)
DK (1) DK1949903T3 (enExample)
ES (2) ES2273599B1 (enExample)
MX (1) MX2008004886A (enExample)
RU (1) RU2445099C2 (enExample)
WO (1) WO2007045705A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3088900B1 (en) * 2011-10-17 2020-08-12 Roche Diagniostics GmbH Troponin as marker for intermittent atrial fibrillation
CZ2014307A3 (cs) * 2014-05-06 2016-01-13 Vysoká škola chemicko- technologická v Praze Kofein-8-hydrazony jako nová cytostatika pro léčbu onkologických onemocnění
WO2017008205A1 (en) * 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
CN108570054B (zh) * 2017-03-07 2021-07-16 广州再极医药科技有限公司 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用
JP7478673B2 (ja) 2018-06-04 2024-05-07 エクスシエンティア・エルティーディー アデノシン受容体アンタゴニストとしてのピラゾロピリミジン化合物
CN108864114B (zh) * 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
EP4146341A4 (en) * 2020-05-06 2024-06-26 Ohio State Innovation Foundation Compositions and methods for treating atrial fibrillation
KR102675647B1 (ko) * 2021-06-30 2024-06-18 단국대학교 천안캠퍼스 산학협력단 인간치아줄기세포의 상아모세포로의 분화를 위한 신규 화합물 및 이의 의학적 용도

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US599387A (en) * 1898-02-22 Cabinet
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US4780464A (en) * 1986-12-08 1988-10-25 Warner-Lambert Company (1,2,4)triazolo(4,3-a)quinoxaline-4-amines
EP0559893B1 (en) 1990-10-18 1999-02-03 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivative
GB9124968D0 (en) * 1991-11-25 1992-01-22 Ici Plc Chemical process
US5484920A (en) 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
CA2116967C (en) 1992-07-08 2003-08-19 Fumio Suzuki Antidepressants
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
WO1995003806A1 (en) 1993-07-27 1995-02-09 Kyowa Hakko Kogyo Co., Ltd. Remedy for parkinson's disease
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
US5703085A (en) 1994-02-23 1997-12-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
US6051578A (en) * 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
JP4195729B2 (ja) 1997-03-24 2008-12-10 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
ES2264210T3 (es) 1997-09-05 2006-12-16 Kyowa Hakko Kogyo Co., Ltd. Derivados de xantina para el tratamiento de la isquemia cerebral.
EP0975345A1 (en) 1997-11-26 2000-02-02 Cerebrus Pharmaceuticals Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
WO1999035147A1 (en) 1998-01-05 1999-07-15 Eisai Co., Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
AU2639299A (en) 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease
DE19930558A1 (de) 1998-07-24 2000-01-27 Marquardt Gmbh Elektrischer Schalter
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
AU748612B2 (en) * 1998-09-04 2002-06-06 Procter & Gamble Company, The Substituted dihydrobenzopyrans useful as antiarrhythmic agents
AU4431000A (en) 1999-05-12 2000-12-05 Fujisawa Pharmaceutical Co., Ltd. Novel use
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
GB9915437D0 (en) 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
ES2246867T3 (es) 1999-07-02 2006-03-01 Eisai Co., Ltd. Compuestos de imidazol condensados y medicamentos contra la diabetes mellitus.
JP3347691B2 (ja) * 1999-07-05 2002-11-20 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド 抗不整脈及び抗細動剤として有用な新規４−オキソ環式尿素類
HK1049835B (zh) 1999-08-31 2005-04-08 范德比尔特大学 A2b腺苷受体的选择性拮抗剂
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
DE19947154A1 (de) 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
US6194366B1 (en) 1999-11-16 2001-02-27 Esc, Inc. Post chemical-mechanical planarization (CMP) cleaning composition
AUPQ441499A0 (en) 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
EP1261327B1 (en) 2000-02-25 2005-04-27 F.Hoffmann-La Roche Ag Adenosine receptor modulators
WO2001080893A1 (en) 2000-04-26 2001-11-01 Eisai Co., Ltd. Medicinal compositions promoting bowel movement
IL152726A0 (en) 2000-05-26 2003-06-24 Schering Corp Adenosine a2a receptor antagonists
JP3886897B2 (ja) 2000-06-21 2007-02-28 エフ．ホフマン−ラ ロシュ アーゲー ベンゾチアゾール誘導体
HUP0700086A2 (en) 2000-08-11 2007-05-29 Eisai Co Ltd 2-aminopyridine compounds, use thereof as drugs and pharmaceutical compositions containing them
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
AR037243A1 (es) 2001-10-15 2004-11-03 Schering Corp Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
US6599901B1 (en) * 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
HUP0402324A3 (en) 2001-11-30 2008-09-29 Schering Corp [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine derivatives as adenosine a2a receptor antagonists and pharmaceutical compositions containing them
PE20030739A1 (es) 2001-11-30 2003-08-28 Schering Corp Antagonistas del receptor de adenosina a2a
HUP0402018A3 (en) 2001-11-30 2008-06-30 Schering Corp 5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them
ES2279903T3 (es) 2001-12-18 2007-09-01 Cv Therapeutics, Inc. Antagonistas del receptor a2a de adenosina.
US20050043315A1 (en) 2002-01-02 2005-02-24 Hideo Tsutsumi Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
ES2208063B1 (es) 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
AU2002950853A0 (en) 2002-08-19 2002-09-12 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compound and pharmaceutical use thereof
CA2496920A1 (en) 2002-08-30 2004-03-11 Kyowa Hakko Kogyo Co., Ltd. Adenosine a2a receptor antagonists for treating restless legs syndrome or related disorders
WO2004029056A1 (ja) 2002-09-24 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. [１，２，４]トリアゾロ[１，５−ｃ]ピリミジン誘導体
EP2295047A3 (en) 2002-12-19 2011-05-18 Schering Corporation Use of adenosine A2a receptor antagonists for the treatment of restless leg syndrome and other movement disorders
CA2520251A1 (en) * 2003-03-27 2004-10-07 Pfizer Products Inc. Substituted 4-amino[1,2,4]triazolo[4,3-a]quinoxalines
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
PT1622912E (pt) 2003-04-23 2009-08-17 Schering Corp Antagonistas 2-alcinil- e 2-alcenilpirazolo-[4,3-b]-1,2,4- triazolo-[1,5-c]-pirimidina do receptor a2a da adenosina
DK1673354T3 (da) 2003-10-03 2009-07-27 Ortho Mcneil Janssen Pharm Arylindenopyridiner og arylindenopyrimidiner og deres anvendelse som adenosin-A2a-receptorantagonister
CA2543644A1 (en) 2003-10-27 2005-05-06 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
TW200524887A (en) 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
ATE377599T1 (de) 2003-12-01 2007-11-15 Schering Corp Verfahren zur herstellung von substituierten 5- aminopyrazolo(4,3-e)-1,2,4-triazolo(1,5- c)pyrimidinen
AU2004299461A1 (en) 2003-12-15 2005-06-30 Almirall Ag 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists

Also Published As

Publication number Publication date
CN101325956B (zh) 2012-02-29
AU2006303240A1 (en) 2007-04-26
ES2273599A1 (es) 2007-05-01
US20090312332A1 (en) 2009-12-17
EP1949903B1 (en) 2012-04-18
AU2006303240B2 (en) 2012-07-12
CA2626020A1 (en) 2007-04-26
RU2445099C2 (ru) 2012-03-20
CN101325956A (zh) 2008-12-17
ES2273599B1 (es) 2008-06-01
EP1949903B8 (en) 2012-05-23
ES2386377T3 (es) 2012-08-20
MX2008004886A (es) 2009-03-02
BRPI0617369A2 (pt) 2011-07-26
US8012973B2 (en) 2011-09-06
RU2008118995A (ru) 2009-11-20
JP2009511551A (ja) 2009-03-19
WO2007045705A2 (es) 2007-04-26
DK1949903T3 (da) 2012-07-30
EP1949903A2 (en) 2008-07-30
WO2007045705A3 (es) 2007-06-14

Similar Documents

Publication Publication Date Title
NO20072548L (no) Xantinderivater med HM74A reseptoraktivitet
ATE453642T1 (de) Substituierte phenylaminopyrimidine
ATE316077T1 (de) Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
EP1850658A4 (en) IMPROVED PROCESS FOR THE TREATMENT OF DEGENERATIVE DISEASES OF RETINA
CY1115617T1 (el) Χρηση της εποθιλονης κατα τη θεραπευτικη αγωγη νοσηματων τα οποια σχετιζονται με την πρωτεϊνη ταu εις τα οποια συμπεριλαμβανεται η νοσος του αlzheimer
EP1951319A4 (en) Chimeric immunoreceptor useful in treating human cancers
NO20043411L (no) Substituerte quinazolin-4-ylamin analoger
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
NO20071243L (no) Substituterte biarylpiperazinylpyridinanaloger.
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
NO20060027L (no) Antistoffer mot bindevevsvekstfaktor
MY142067A (en) Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease
NO20070293L (no) Aryl-substituerte piperazinderivater
ATE453646T1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
WO2005007652A3 (en) Substituted quinolin-4-ylamine analogues
WO2005023807A3 (en) 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
ATE553763T1 (de) Selektive a2a-rezeptorantagonisten zur behandlung von vorhofflimmern
WO2006081388A3 (en) Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение
CY1112568T1 (el) Χρηση των πυριμιδυλαμινοβενζαμιδων για τη θεραπεια των νοσων που ανταποκρινονται στην ρυθμιση της δρασης της τιε-2 κινασης
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
CL2004000677A1 (es) Compuestos derivados de piperidinas; procedimiento de preparacion; composicion farmaceutica; utiles como moduladores de la actividad del receptor de quimioquina en el tratamiento de enfermedades autoinmunes, inflamatorias, proliferativas o mediadas i
WO2005084401A3 (en) Aryl substituted purine analogues